Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
August 22, 2023 09:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
August 02, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
Alvotech Completes $100 Million Convertible Bond Private Placement
July 31, 2023 04:00 ET
|
Alvotech
REYKJAVIK, Iceland, July 31, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023 19:00 ET
|
Alvotech
REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech birtir upplýsingar um stöðu umsóknar um markaðsleyfi í Bandaríkjunum fyrir AVT02
June 28, 2023 19:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefði sent svar við annarri umsókn félagsins um markaðsleyfi fyrir AVT02, sem jafnframt inniheldur gögn sem...
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
June 28, 2023 19:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
June 27, 2023 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
June 22, 2023 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech og Teva ná samningi um upphafsdag sölu á AVT04, líftæknilyfjahliðstæðu við Stelara®, í Bandaríkjunum
June 12, 2023 03:00 ET
|
Alvotech
Samkvæmt samningnum má sala á AVT04 (ustekinumab) hefjast í Bandaríkjunum eigi síðar en 21. febrúar 2025, að fengnu samþykki lyfjayfirvalda Alvotech (NASDAQ: ALVO) og Teva Pharmaceuticals Inc.,...
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023 03:00 ET
|
Alvotech
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 Alvotech (NASDAQ: ALVO), a global biotech company...